Megh Gupta
Investor @ Nurx
Toronto, Canada
Megh Gupta is a Series A investor at Nurx in Toronto focused on Health Care and Medical. Megh Gupta - Partner @ Wittington Ventures
- Total investments:
- 5
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Megh Gupta invests in
Stages Megh Gupta invests in
Countries Megh Gupta invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 3 (60%)
- Medical 1 (20%)
- Internet 1 (20%)
- Life Science 1 (20%)
- Biotechnology 1 (20%)
Stage
- Series A 2 (40%)
- Series C 1 (20%)
- Series D 1 (20%)
- Funding Round 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
WellBeam
|
WellBeam is an operator of a connected care platform intended to help hospitals connect with third party clients. | $10M / Series A / Nov 19, 2025 | |
Truvian Sciences
|
Truvian disrupts the blood-testing industry by developing an automated, benchtop diagnostic system to provide lab-accurate results.The blood-testing system combines chemistry, immunoassays, and hematology assays in one device. With its 20-minute, single-run wellness panel that requires only several drops of blood, the company aims to cover about40 commonly ordered diagnostic tests, including a lipid panel, metabolic panel, and complete blood cell count. Its dry reagent and optical sensing technologies, which require no refrigeration, can perform a complete blood count, basic metabolic and lipid panel, hemoglobin and glucose tests, thyroid screenings, and liver and kidney function exams. The company also offers Easy Check, a blood-based serologic test Truvian claims can detect the presence of the antibodies effective against SARS-CoV-2, the virus that causes COVID-19.Dena Marrinucci, Kim Kamdar, Mark Bowles, and Pieter van Rooyen established the San Diego, California-based company in 2015. | $74M / Jul 17, 2024 | |
|
Truvian Sciences
|
Truvian disrupts the blood-testing industry by developing an automated, benchtop diagnostic system to provide lab-accurate results.The blood-testing system combines chemistry, immunoassays, and hematology assays in one device. With its 20-minute, single-run wellness panel that requires only several drops of blood, the company aims to cover about40 commonly ordered diagnostic tests, including a lipid panel, metabolic panel, and complete blood cell count. Its dry reagent and optical sensing technologies, which require no refrigeration, can perform a complete blood count, basic metabolic and lipid panel, hemoglobin and glucose tests, thyroid screenings, and liver and kidney function exams. The company also offers Easy Check, a blood-based serologic test Truvian claims can detect the presence of the antibodies effective against SARS-CoV-2, the virus that causes COVID-19.Dena Marrinucci, Kim Kamdar, Mark Bowles, and Pieter van Rooyen established the San Diego, California-based company in 2015. | $74M / Series D / Jul 17, 2024 | |
Abridge
|
Abridge provides an AI platform that transforms patient-clinician conversations into structured, billable clinical notes. This technology aims to reduce documentation burdens for clinicians and nurses. The system integrates into existing healthcare workflows and electronic health record systems. | $12.5M / Series A / Aug 11, 2022 | |
|
Truvian Sciences
|
Truvian disrupts the blood-testing industry by developing an automated, benchtop diagnostic system to provide lab-accurate results.The blood-testing system combines chemistry, immunoassays, and hematology assays in one device. With its 20-minute, single-run wellness panel that requires only several drops of blood, the company aims to cover about40 commonly ordered diagnostic tests, including a lipid panel, metabolic panel, and complete blood cell count. Its dry reagent and optical sensing technologies, which require no refrigeration, can perform a complete blood count, basic metabolic and lipid panel, hemoglobin and glucose tests, thyroid screenings, and liver and kidney function exams. The company also offers Easy Check, a blood-based serologic test Truvian claims can detect the presence of the antibodies effective against SARS-CoV-2, the virus that causes COVID-19.Dena Marrinucci, Kim Kamdar, Mark Bowles, and Pieter van Rooyen established the San Diego, California-based company in 2015. | $105M / Series C / Feb 24, 2021 |
Co-Investors
7wire Ventures
3 deals together
DNS Capital
3 deals together
GreatPoint Ventures
3 deals together
TYH Capital
3 deals together
Medical Excellence Capital
2 deals together
Tao Capital Partners
2 deals together
About Nurx
Nurx is a digital healthcare company offering 10 services across reproductive health, at-home testing, dermatology, migraine care, and more. Nurx offers patients transparent pricing and judgement-free care whenever and wherever works best for them. Nurx believes everyone should have the freedom to live well and be in charge of their healthcaredecisions, regardless of their circumstances.
Nurx Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Agustin Vilaseca
Staff Software Engineer
|
|||
|
Allison Berry
Director of Brand & Communications
|
|||
Christopher Maxwell
Vice President Of Engineering
|
|||
Edvard Engesæth
Co-Founder
|
|||
Isaac Sparling
Sr Engineering Manager -- Core Services
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Megh Gupta invest in?
Megh Gupta invests primarily in Health Care, Medical and Internet startups, most often at Series A and Series C stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Megh Gupta?
Public channels for Megh Gupta include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Megh Gupta last invest?
The most recent investment recorded for Megh Gupta closed in Nov 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
